DelveInsight, “Myopia – Pipeline Insight, 2023,” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Myopia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Download the sample page to know more @ Myopia Pipeline
- The Key Companies working in Myopia include Vyluma, Sydnexis, Ocumension limited, Santen Pharmaceutica, Cloudbreak Therapeutics, and many others.
- The Key Therapies working in Myopia include NVK002, MicroPine, and many others
Got queries? Click here to learn more about the Myopia Pipeline
Myopia Overview
Myopia, commonly referred to as shortsightedness, is a common cause of visual disability throughout the world. The prevalence of myopia varies by country and by ethnic group, reaching as high as 70-90% in some Asian populations. Myopia occurs if the eyeball is too long or the cornea (the clear front cover of the eye) is too curved. As a result, the light entering the eye isn’t focused correctly, and distant objects look blurred. While the exact cause of myopia is unknown, there is significant evidence that many people inherit myopia, or at least the tendency to develop myopia.
Myopia Epidemiological Segmentation
- Myopia Total Prevalent Cases
- Myopia Severity-specific Prevalence
- Myopia Age-specific Prevalence
- Myopia Diagnosed and Treated cases
Major Players in Myopia
There are approx. 10+ key companies that are developing therapies for Myopia. The companies that have their Myopia drug candidates in the most advanced stage, i.e. Phase III include, Vyluma
Phases
DelveInsight’s Report covers around 12+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
Myopia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
Molecule Type
Products have been categorized under various Molecule types such as
- Oligonucleotide
- Peptide
- Small molecule
Product Type
Drugs have been categorized under various product types like Mono Combination and Mono/Combination.
Table of Contents
- Key Insights
- Report Introduction
- Executive Summary of Myopia
- Disease Background and Overview
- Epidemiology and patient population
- Myopia Emerging Therapies
- Myopia Market Outlook
- Market Access and Reimbursement of Therapies
- Appendix
- Myopia Report Methodology
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
Click here to read more about Myopia pipeline
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services